Related by context. All words. (Click for frequent words.) 79 Kaplan Meier 78 Kaplan Meier survival 78 Kaplan Meier analysis 72 univariate 70 multivariate Cox 70 multivariate logistic regression 70 proportional hazards 69 conditional logistic regression 69 Poisson regression 68 Kaplan Meier curves 68 multivariable logistic regression 68 Univariate 67 Logistic regression 67 logistic regression 67 multiple logistic regression 67 nomogram 67 multivariable Cox 67 logistic regression analyzes 66 univariate analysis 66 logistic regression models 66 logistic regression analysis 66 nonparametric 66 biochemical recurrence 66 Descriptive statistics 66 HOMA IR 65 multivariate analyzes 65 MDRD 65 Mantel Haenszel 65 logistic regression model 65 univariate analyzes 64 prospectively defined 64 Multivariate analysis 64 pCR 64 Multivariate logistic regression 64 confidence intervals CIs 64 Multiple logistic regression 64 biochemical relapse 64 Kruskal Wallis test 64 immunohistochemical analysis 64 myocardial viability 63 multiple linear regression 63 EBMT criteria 63 resected pancreatic cancer 63 preoperative PSA 63 PSADT 63 Kaplan Meier curve 63 FDG-PET/CT 63 covariate 63 Kaplan Meier estimates 63 PSA nadir 63 Multivariable 63 progression TTP 63 regression analyzes 63 HER2 expression 63 histological subtype 63 Index CDAI 63 Solid Tumors RECIST 63 BODE index 63 intact parathyroid hormone 62 odds ratios ORs 62 multivariable analysis 62 Response Evaluation Criteria 62 RECIST Response Evaluation Criteria 62 multivariate regression analysis 62 ImmuKnow assay 62 Subgroup analysis 62 Histologic 62 ROC curves 62 % CI #.#-#.# [003] 62 neoadjuvant chemotherapy 62 NIHSS 62 binary logistic regression 62 meta regression 62 BEXXAR Therapeutic Regimen 62 Linear regression 61 Pearson correlation coefficients 61 neoadjuvant therapy 61 K ras mutations 61 underwent surgical resection 61 FOLFOX4 61 undetectable HBV DNA 61 bivariate 61 transcranial Doppler ultrasound 61 chi squared 61 F FDG PET 61 Secondary endpoints included 61 preoperative chemotherapy 61 Pearson correlation coefficient 61 posttreatment 61 serum HCV RNA 61 clinico pathological 61 nomograms 61 Crohn Disease Activity 61 HIV tropism 60 RECIST criteria 60 CR nPR 60 NMIBC 60 postoperative chemotherapy 60 locoregional 60 multivariable adjusted 60 FDG PET scans 60 transvaginal sonography 60 KRAS status 60 oncologic outcomes 60 retrospective cohort 60 NIHSS score 60 Bonferroni 60 postintervention 60 SLN biopsy 60 Multivariate 60 Sentinel Lymph Node Biopsy 60 specific antigen PSA 60 NIH CPSI 60 tumor histology 60 mean ± SEM 60 mRS 60 colorectal adenoma 60 #.#ng/ml 60 #Gy 60 PSA kinetics 60 Secondary efficacy endpoints 60 remission CR 60 Median progression 60 Glomerular filtration rate 60 sirolimus eluting stents 60 histologic 60 spirometric 60 transient elastography 59 histopathologic examination 59 adenoma recurrence 59 hip resurfacing arthroplasty 59 serum biomarkers 59 Histological 59 Univariate analysis 59 baseline LDH 59 NSABP B 59 ANCOVA 59 System IPSS 59 chest radiographs 59 Folfox 59 DAS# CRP 59 prospectively stratified 59 Preoperatively 59 postoperative complication 59 genotypic resistance 59 nodal metastasis 59 p = #.# [003] 59 Lymph node 59 liver metastasis 59 virologic responses 59 RRM1 59 interobserver reliability 59 dimensional echocardiography 59 mL/min/#.# m 2 59 covariance ANCOVA 59 intraobserver 59 FDG PET CT 59 histopathologic findings 59 Multiple linear regression 59 Hazard Ratio HR 59 Logistic regression analysis 59 % Confidence Interval 59 prognostic variables 59 TIMP 1 59 meta analytic 59 histopathologic diagnosis 59 androgen suppression 59 acetabular fractures 59 liver transplant recipients 59 serum HBV DNA 58 urothelial carcinoma 58 unpaired t 58 interrater reliability 58 MMSE score 58 Bonferroni correction 58 treat NNT 58 RECIST 58 MTT assay 58 virological response 58 Visual Analogue Scale VAS 58 chemoradiotherapy 58 glomerular filtration rate 58 explanatory variables 58 variance ANOVA 58 antidiabetic medication 58 adjuvant cisplatin 58 allele frequencies 58 BRCA2 mutation carriers 58 clinicopathological 58 transthoracic 58 HIV RNA 58 ANOVA 58 serum urate 58 thyroglobulin 58 Tumor Response 58 inhibin B 58 pairwise comparisons 58 induced sputum 58 multivariate regression 58 percutaneous biopsy 58 regression coefficient 58 Insulin sensitivity 58 postoperative mortality 58 sonographically guided 58 SUVmax 58 histologic findings 58 Main Outcome Measure 58 lactate dehydrogenase LDH 58 median survivals 58 dacarbazine chemotherapy 58 liver biopsies 58 dosimetric 58 CIMZIA ™ 58 peak VO2 58 renal cell carcinomas 58 generalized estimating 58 estimated glomerular filtration 58 QTcF 58 nonmetastatic 58 Randomized clinical trials 58 tipranavir ritonavir 58 NHANES III 58 TNM staging 58 pancreatic adenocarcinoma 58 gemcitabine carboplatin 58 vincristine doxorubicin 58 glomerular filtration 58 immunohistochemical staining 58 squamous histology 58 Interrater reliability 58 WOMAC pain 58 EUS FNA 58 Histopathologic 58 pathologic diagnosis 58 Carotid Revascularization Endarterectomy vs. 58 μmol L 58 Kaplan Meier estimate 58 neurologic progression 58 bone scintigraphy 58 histologic subtype 58 linear regression analyzes 58 differentially expressed genes 58 ADAS cog 58 gadolinium enhanced 58 DAS# scores 58 microalbumin 58 FDG PET imaging 58 Sensitivity analyzes 58 antithymocyte globulin 57 interobserver 57 estimated GFR 57 covariance 57 generalized linear 57 paricalcitol 57 transrectal ultrasound guided 57 ASCUS 57 nondiabetic patients 57 methotrexate monotherapy 57 octreotide LAR 57 serum clusterin levels 57 external beam radiotherapy 57 relapsed MM 57 pT2 57 galiximab 57 Pharmacokinetic parameters 57 distant metastasis 57 Median PFS 57 statistical significance p 57 standard chemotherapy regimen 57 prostate cancer PCa 57 creatinine clearance 57 XELOX 57 Primary endpoints 57 breast carcinoma 57 Wilcoxon rank sum 57 advanced adenoma 57 eNO 57 DLQI 57 Secondary endpoints 57 oocytes retrieved 57 Subgroup analyzes 57 Cardiorespiratory fitness 57 posttransplant 57 regression coefficients 57 XIENCE V PROMUS Stent 57 sensitivity specificity 57 timepoints 57 periprocedural 57 rFSH 57 transabdominal 57 radiochemotherapy 57 antiangiogenic therapy 57 clodronate 57 advanced neoplasia 57 complete cytogenetic response 57 LV dysfunction 57 Postoperative complications 57 coronary stenosis 57 linear regression 57 5-fluorouracil/leucovorin 57 florbetaben 57 Ceplene/IL-2 57 Secondary endpoints include 57 vastus lateralis 57 P = .# 57 Radical prostatectomy 57 nephrectomy 57 prostate carcinoma 57 advanced adenomas 57 Immunohistochemical analysis 57 metachronous 57 posttest 57 cytologic 57 plus dexamethasone 57 angiographic restenosis 57 FOLFIRI alone 57 KRAS mutations occur 57 surgically resected 57 APACHE II 57 prognostic indicators 57 interquartile range 57 HBeAg seroconversion 57 preintervention 57 covariates 57 FDG PET 57 sleeve lobectomy 57 CR CRu 57 pT3 57 axillary dissection 57 Computed tomographic 57 lactate dehydrogenase 57 perioperative mortality 57 ultrasonographic 57 Cancer Incidence Mortality 57 hemoglobin A1c levels 57 Cystatin C 57 logistic regressions 57 pretransplant 57 Free Survival PFS 57 GAMMAGARD 57 immunohistochemical 57 androgen deprivation 57 esophageal carcinoma 57 mammographic density 57 baseline FEV 57 leukocyte count 57 Papillary 57 semiquantitative 57 serum estradiol 57 Non inferiority 57 tumor progression TTP 57 nodal metastases 57 lymphocyte count 57 DAS# remission 57 pretreatment serum 57 SLNB 57 albumin excretion rate 57 VcMP 57 TRUS 57 Liver biopsies 57 multivariate analysis 57 Common Toxicity Criteria 57 lowest tertile 57 endometrial thickness 57 Viral load 57 KRAS mutation 57 prostate cancer CaP 57 cranial irradiation 57 Randomized trials 57 linear regression analysis 57 concurrent chemoradiation 56 ductal carcinomas 56 Supplementary Table 56 secondary efficacy endpoint 56 adjuvant tamoxifen 56 histopathologic 56 debulking surgery 56 ± SEM 56 clinicopathological features 56 recurrent venous thromboembolism 56 neoadjuvant 56 hSBA 56 differential gene expression 56 Angiographic 56 CC genotype 56 mITT population 56 Timed Walk 56 creatinine ratio 56 preoperatively 56 lumbar spine BMD 56 distant metastases 56 Platelet counts 56 Brief Psychiatric 56 clinically meaningful improvement 56 radical retropubic prostatectomy 56 serum aminotransferase levels 56 pathologic examination 56 hormone receptor status 56 etiologic 56 transcranial Doppler 56 recurrent glioblastoma multiforme 56 -#.# log# copies mL 56 stage IIIb IV 56 core needle biopsies 56 locoregional recurrence 56 radiotherapy RT 56 Unified Parkinson Disease 56 TIMP 56 serum concentrations 56 SpCO 56 IL#B 56 operable pancreatic cancer 56 histologically proven 56 bivariate analysis 56 % CI #.#-#.# [007] 56 CRp 56 convergent validity 56 PCI ExTRACT TIMI 56 TLUS 56 antibody titer 56 DEXA scans 56 surrogate endpoint 56 mitoxantrone chemotherapy 56 glycosylated hemoglobin HbA1c 56 APOE genotype 56 ARB telmisartan 56 stepwise logistic regression 56 morphometric vertebral fractures 56 Hb A1C 56 doxorubicin cyclophosphamide 56 unresectable tumors 56 KRAS mutations 56 platelet reactivity 56 metabolic parameters 56 CIN2 + 56 categorical variables 56 nodular partial response 56 HER2 positivity 56 NAMCS 56 regression equations 56 poor metabolizers 56 QTc prolongation 56 postoperative radiographs 56 ^ sup #m 56 T1a 56 efficacy evaluable 56 symptomatic VTE 56 multicenter randomized controlled 56 troponins 56 hyperinsulinemic euglycemic clamp 56 TRUS biopsy 56 Sentinel Lymph Node 56 β blockers 56 recurrent metastatic 56 Xelox 56 lymphovascular invasion 56 HBV DNA 56 axillary lymph nodes 56 chemoradiation therapy 56 anthropometric measures 56 Doxil ® 56 ug dose 56 randomized controlled trials RCTs 56 serum PSA 56 Estrogen Receptor 56 axillary node dissection 56 binary restenosis 56 mediated dilation 56 Doppler echocardiography 56 Ejection Fraction 56 mycophenolate mofetil 56 linear regressions 56 pharmacokinetic parameters 56 apparent diffusion coefficient 56 ADCS CGIC 56 bronchoalveolar lavage fluid 56 FOLFIRI 56 melphalan prednisone 56 radical nephrectomy 56 AST ALT 56 scintigraphic 56 coronary calcification 56 rho = 56 Main Outcome Measures 56 plus medroxyprogesterone acetate 56 prognostic significance 56 biopsy Gleason 56 pharmacodynamic parameters 56 IPAH 55 neurocognitive function 55 Thrombolysis 55 curative resection 55 doxorubicin docetaxel 55 Partial Responses 55 d dimer 55 randomized multicenter Phase III 55 colorectal adenocarcinoma 55 carotid plaque 55 retrospectively analyzed 55 subanalysis 55 mg kg dose 55 Alzheimer Disease Assessment 55 pre operatively 55 leiomyoma 55 angiographically 55 SVR# 55 Rating Scale UPDRS 55 seminal vesicle invasion 55 Pain Intensity 55 MDRD equation 55 lung nodule 55 mediastinal lymph nodes 55 mCRC patients 55 CCyR 55 HCT# 55 response pCR 55 leukocyte counts 55 mg/m2 dose 55 cytogenic 55 ECD kidneys 55 cytoreduction 55 anthropometric measurements 55 microdebrider 55 Multivariate analyzes 55 Doppler ultrasonography 55 perioperative morbidity 55 chemoembolization 55 computed tomographic scan 55 Doppler sonography 55 Prostate specific antigen 55 composite endpoint 55 TOP2A 55 MR spectroscopy 55 HSCT 55 EQ 5D 55 electrophysiologic 55 Regression analysis 55 differentiate squamous 55 Immunohistochemical staining 55 sustained virological response 55 Stage IIIb 55 χ 55 heterozygotes 55 FOLPI 55 normal karyotype 55 ischemic lesions 55 Health Assessment Questionnaire 55 RECORD1 55 correlation coefficients 55 intraventricular 55 subtrochanteric 55 RQ PCR 55 Visual Analog Scale 55 genotypic 55 aminotransferase levels 55 clinically localized prostate 55 pegylated liposomal doxorubicin 55 Cockcroft Gault 55 transcriptional profiling 55 prognostic indicator 55 -#.# log# 55 polygonal method 55 Adjuvant chemotherapy 55 dose proportionality 55 invasive ductal 55 ertapenem 55 NYHA functional class 55 lognormal 55 radiation dosimetry 55 pmol L 55 Coronary Artery Bypass Graft 55 Pharmacokinetic 55 nucleotide substitutions 55 Rectal cancer 55 locoregional disease 55 locoregional control 55 siRNA knockdown 55 CSF biomarkers 55 Framingham Risk Score 55 node metastases 55 Postoperative 55 ERCC1 55 lateral radiographs 55 endometrial carcinoma 55 mucinous 55 atorvastatin #mg 55 hematopoietic cancers 55 KRAS wild 55 elevated LDH 55 diffusion tensor 55 hyperintense lesions 55 intradermal injections 55 SEER registry 55 pharmacodynamic effects 55 squamous 55 sipuleucel T 55 HBV DNA levels 55 actigraphy 55 postmenopausal hormone 55 paclitaxel eluting stents 55 seropositivity 55 GnRH agonists 55 TURBT 55 abacavir lamivudine 55 Kruskal Wallis 55 STRIDE PD 55 GnRH agonist 55 aspartate aminotransferase AST 55 HIV HCV coinfected 55 HbA 1c levels 55 Operative mortality 55 inhaled budesonide 55 5-FU/LV 55 hepatic arterial 55 underwent resection 55 Platinol ® cisplatin 55 recursive partitioning 55 HCCs 55 oblimersen 55 Symptom severity 55 median PFS 55 proximal femur 55 postprocedure 55 MERIT ES 55 Histopathological 55 Capacity FVC 55 adjuvant systemic 55 definite stent thrombosis 55 Diabetic Foot Ulcer 55 serum albumin 55 variant allele 55 cisplatin resistant 55 histopathological 55 urinary N telopeptide 55 lymphocytosis 55 cTnT levels 55 transrectal ultrasound 55 HORIZONS AMI trial 55 glycated hemoglobin levels 55 PET CT colonography 55 Natalizumab 55 HER2 amplification 55 microsimulation model 55 tertile 55 resectable pancreatic cancer 55 SELDI TOF MS 55 β blocker 55 Rate ORR 55 intima media thickness IMT 55 intraoperatively 55 virologic failure 55 maximal treadmill 55 Liver biopsy 55 immunosuppressive regimen 55 Pemetrexed 55 Genotypic 55 pelvic lymphadenectomy 55 urinary albumin 55 cTnI 55 HER2 overexpression 55 exhaled nitric oxide 54 hepatectomy 54 undergone radical prostatectomy 54 monophasic 54 colorectal liver metastases 54 HAQ DI 54 pharmacokinetics PK 54 asymptomatic carotid stenosis 54 Echocardiographic 54 angiographic outcomes 54 gastric adenocarcinoma 54 creatine kinase MB 54 Supplementary Appendix 54 plasma cortisol 54 plasma leptin 54 Clinician Administered PTSD 54 arterial thickening 54 Scale cognitive subscale 54 transgene expression 54 epirubicin cyclophosphamide 54 graft dysfunction 54 OPCAB 54 KRAS mutation status 54 hip BMD 54 Brief Pain 54 HGPIN 54 virologic response 54 cEVR 54 attain statistical significance 54 hemodynamic variables 54 biopsy specimens 54 Prostate Cancer Prevention 54 F FDG uptake 54 pharmacodynamic PD 54 invasive carcinomas 54 Oncotype DX Recurrence Score 54 nonresponders 54 ALND 54 Preoperative 54 Cytogenetic 54 cytogenetic abnormalities 54 periprocedural MI 54 ACR# responses 54 calculated creatinine clearance 54 IFN α 54 Hemoccult II 54 immunostaining 54 urodynamic 54 PASI scores 54 ordinary Kriging 54 lung metastasis 54 PITX2 methylation 54 serum testosterone 54 detectable HCV RNA 54 multivariable 54 ^ Tc 54 subgroup analyzes 54 p = .# [002] 54 #F FDG PET 54 transfection efficiency 54 radical prostatectomy RP 54 Immunohistochemical 54 death reinfarction 54 orthologous genes 54 sentinel lymph node 54 HbA1C levels 54 intravital 54 ADCS ADL 54 NSTE ACS 54 plus prednisone 54 precursor lesions 54 variant rs# 54 tPSA 54 hierarchical clustering 54 preoperative staging 54 methacholine challenge 54 mutated K ras 54 Psoriasis Area 54 EGFR TKI 54 murine models 54 histologically 54 transcriptional profiles 54 mg BID dose 54 docetaxel pretreated 54 adjuvant radiation 54 micrometastasis 54 placebo dexamethasone 54 endometrial hyperplasia 54 prospectively randomized 54 intermittent dosing 54 serum magnesium 54 saline placebo 54 acetabular fracture 54 perioperative complications 54 chromatograms 54 papillary renal cell carcinoma 54 hematological relapse 54 HBeAg negative 54 adjuvant therapies 54 nonfatal MI 54 pain palliation 54 flutamide 54 YMRS 54 creatinine clearance CrCl 54 DSM IV diagnoses 54 IgG antibody 54 CYP#D# inhibitor 54 cystatin C 54 extracolonic findings 54 tumor subtype 54 preoperative intraoperative 54 Prospective Randomized Trial 54 5 Fluorouracil 54 ejection fractions 54 echocardiographic parameters 54 ibandronate 54 TAXUS Express Stent 54 tumor biopsies 54 aldosterone antagonist 54 conventional angiography 54 Kloski noted 54 unfractionated heparin UFH 54 computed tomographic scans 54 cystectomy 54 idraparinux 54 QIDS SR 54 cGy 54 median CD4 54 urine cytology 54 EuroSCORE 54 Sprague Dawley rats 54 SCr 54 parous women 54 HBeAg negative patients 54 intramyocardial 54 intratumoral 54 ELBW infants 54 microarray experiments 54 serum leptin 54 BALF 54 hours postdose 54 FDG uptake 54 extracapsular extension 54 neoadjuvant radiation 54 GSTP1 54 prospective multicentre 54 hepatorenal syndrome 54 cytoreductive nephrectomy 54 SEER database 54 Mammographic 54 tissue microarrays 54 ETDRS 54 chemosensitivity 54 renal tumors 54 ADAS Cog 54 Stenting Trial CREST 54 FOLFIRINOX 54 observational cohort 54 percutaneous vertebroplasty 54 endometrioid 54 efavirenz EFV 54 neointimal 54 Glomerular Filtration Rate 54 -#.# ± [002] 54 GLIADEL R Wafer 54 #S rRNA gene 54 RRs 54 nutlin 3a 54 fluvastatin 54 microvessel density 54 everolimus eluting stents 54 evaluable subjects 54 rosuvastatin #mg 54 APTIVUS r 54 Seattle Angina Questionnaire 54 adriamycin 54 ALT elevation 54 confidence interval #.#-#.# 54 Pharmacodynamic 54 peritoneal carcinomatosis 54 HRCT 54 chest radiograph 54 mcg albinterferon alfa 2b 54 morphometric 54 HAM D# 54 prognostic factors 54 CYP#D# genotype 54 eosinophil count 54 microsatellite instability 54 histologically confirmed 54 carotid artery thickness 54 virologic response EVR 54 hematological parameters 54 HIV seroconversion 54 D dimer 54 variography 54 care regimens CCR 54 electron beam computed tomography 54 variograms 54 Adjuvant therapy 54 nadroparin 54 cystoscopic 54 adenoma detection 54 R# #mg BID 54 bFGF 54 wrist actigraphy 54 cardiac perfusion 54 pulmonary angiography 54 stage IIIA 54 serum cortisol 54 graft patency 54 PROSTVAC VF 54 CTEPH 54 renal cortical 54 Visual Analog 54 Introductory teaser rates 54 ritonavir boosted 54 renal cysts 54 evaluable 54 lymphocyte counts 54 invasive lobular 54 HBeAg 54 interferon ribavirin 54 BR.# 54 resected tumors 54 biliary tract cancer 54 BMD measurements 54 troponin T 54 subscale scores 54 virologic breakthrough 54 nadir CD4 cell 54 multivariable analyzes 54 spectrophotometric 54 plasma pharmacokinetics 54 tertiles 54 bioluminescence imaging 54 AJCC 54 GG genotype 54 lymph node involvement 54 EBUS FNA 54 cTnT 54 multivariable regression 54 6MWD 53 BCIRG 53 retrospective observational study 53 varicoceles 53 BEACOPP 53 ovariectomized 53 Partial Response 53 aminotransferases 53 ptau 53 atazanavir ritonavir 53 RE LY ® 53 oral clodronate 53 infliximab monotherapy 53 miRview ™ squamous 53 chemotherapy gemcitabine 53 HoLEP 53 CDAI 53 femoral neck BMD 53 echocardiographic 53 p# Shc 53 ER CHOP 53 fructosamine 53 hsCRP levels 53 tumor regressions 53 azacytidine 53 carcinoembryonic antigen 53 visceral metastases 53 morphologic characteristics 53 familial aggregation 53 neutrophil counts 53 Gaussian distribution 53 mg Pycnogenol 53 liver resection 53 gauge vitrectomy 53 NNT = 53 nonobese patients 53 recurrent GBM 53 RT PCR assay 53 BENICAR HCT 53 primary patency 53 endoscopic gastric ulcers 53 carotid stenosis 53 secondary endpoint 53 Neuropsychiatric Inventory NPI 53 selenium supplementation 53 contralateral breast 53 CALGB 53 Ki# 53 nonoperative 53 tenecteplase 53 Wechsler Adult 53 DCE MRI 53 Mendelian randomization 53 cells mcL 53 Radiographs 53 prespecified secondary 53 urolithiasis 53 incomplete revascularization 53 MDCT angiography 53 CaPSURE 53 histologic diagnosis 53 operable breast cancer 53 TRAIL R1 53 irinotecan cisplatin 53 docetaxel prednisone 53 ABL1 53 regression analysis 53 achieved CCyR 53 pharmacokinetic characteristics 53 log# copies mL 53 elevated transaminases 53 serum CRP 53 serum phosphorous 53 foveal thickness 53 noninferior 53 Clinical Outcome 53 NAbs 53 Bayesian inference 53 enhanced sonography 53 dose dexamethasone 53 radiographically 53 liver histology 53 CHADS2 53 intracoronary 53 nucleated cells 53 Y BOCS 53 Lumbar spine 53 radical cystectomy 53 underwent radical prostatectomy 53 Logistic Regression 53 pulmonary dysfunction 53 Aspergillus nidulans 53 Key secondary endpoints 53 hemostatic efficacy 53 axillary lymph node 53 anastrazole 53 inhospital mortality